Warringal Medical Centre
Welcome,         Profile    Billing    Logout  
 6 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tebbutt, Niall C
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
NEO-IMPACT, NCT06094140: NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Active, not recruiting
2
20
RoW
Durvalumab, Imfinzi, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Campto, Calcium folinate (leucovorin), Folinic acid, Fluorouracil, Adrucil, Pegylated G-CSF, Neulasta
Australasian Gastro-Intestinal Trials Group, The University of New South Wales, Walter and Eliza Hall Institute of Medical Research
Pancreatic Cancer
06/24
06/26
NCT06441747: Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Recruiting
2
40
RoW
Durvalumab, Imfinzi, Olaparib, Lynparza
Australasian Gastro-Intestinal Trials Group, Wayne Elphinstone Research Fund, AstraZeneca
Cholangiocarcinoma
08/26
08/28
ASCEND, NCT05042128: The Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
158
RoW
LSTA1, CEND-1, certepetide, Gemcitabine Injection, Gemzar, Nab paclitaxel, Abraxane
Australasian Gastro-Intestinal Trials Group, University of Sydney
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
06/25
10/25
YH32367-101, NCT05523947: Clinical Trial of YH32367 in Patients with HER2 Positive Locally Advanced or Metastatic Solid Tumor

Recruiting
1/2
137
RoW
YH32367
Yuhan Corporation
HER2-Positive Solid Tumor
10/26
12/26
NCT05427487: Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Recruiting
1
70
RoW
IVX037, Sintilimab
ImmVirx Pty Ltd, Innovent Biologics (Suzhou) Co. Ltd.
Colorectal Cancer, Gastric Cancer, Ovarian Cancer
09/26
11/26
Guo, Yuan
NEO-IMPACT, NCT06094140: NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Active, not recruiting
2
20
RoW
Durvalumab, Imfinzi, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, Campto, Calcium folinate (leucovorin), Folinic acid, Fluorouracil, Adrucil, Pegylated G-CSF, Neulasta
Australasian Gastro-Intestinal Trials Group, The University of New South Wales, Walter and Eliza Hall Institute of Medical Research
Pancreatic Cancer
06/24
06/26
ASCEND, NCT05042128: The Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
158
RoW
LSTA1, CEND-1, certepetide, Gemcitabine Injection, Gemzar, Nab paclitaxel, Abraxane
Australasian Gastro-Intestinal Trials Group, University of Sydney
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
06/25
10/25
Paradise, NCT05671315: A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

Recruiting
N/A
267
RoW
Peginterferon alfa-2b Injection, Nucleos (t) ide Analogue, Nucleos(t)ide analogue
Qing XIe
Chronic Hepatitis B, Intermediate to High Risk of HCC
08/23
04/26

Download Options